JJDC
Venture capitalNew Brunswick · Seed–Series B · 11 people tracked
Find your way into JJDC
1,490 people in our graph share verified history with the JJDC team — schools, employers, funds. One of them is your warm intro.
Investment thesis
JJDC is the venture capital arm of Johnson & Johnson, investing since 1973 across medical devices, diagnostics, pharmaceuticals, and consumer health. The firm provides seed through late-stage venture financing to companies whose technologies and business models align with Johnson & Johnson's strategic interests.
Team · 11 people
from public directories
What they invest in
from 9 of 9 portfolio companiesHealthtech ×7Biotech ×5AI & Machine Learning ×2Data & Infrastructure ×1Deep Tech ×1Digital Health ×1Longevity ×1Medical Devices ×1
HQs:United States×5China×1
Investments · 9 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12024 · 12022 · 12017 · 12016 · 12015 · 17 dated
Protagonist is a company that emphasizes a diverse and inclusive corporate culture as central to its innovation, with stated goals of creating wins for its organization and for patients.
BiotechHealthtechMilpitas, US
Dinesh V. Patel, PhD(Executive Officer, Director)Dinesh Patel(President & Chief Executive Officer)
BoardAsish K. Xavier, Ph.D.(Director)Michael Panaccio, Ph.D.(Director)Armen Shanafelt, Ph.D.(Director)Paul F. Truex(Director)
Co-investorsAisling CapitalCanaan PartnersLilly VenturesStarfish Ventures
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.
BiotechHealthtechLongevity
Co-investorsAtlas VentureDroia VenturesEcoR1 CapitalGV (Google Ventures)The Column GroupJohnson & Johnson Innovation – JJDC+1 more
Data & InfrastructureDigital HealthHealthtechNew York, US
Sebastian G. Schneeweiss(Director)William Geary(Director)inJeremy Rassen(Executive Officer, Director)
Co-investorsB Capital GroupB4 CapitalBlue Lion GlobalFlare Capital PartnersForesite CapitalLG Technology Ventures+6 more
Mestag Therapeutics is an immunology company developing first-in-class agonist antibody therapies for cancer and inflammatory diseases based on fibroblast biology, and operates a RAFT platform for discovering new drug targets.
AI & Machine LearningBiotechHealthtech
Susan Hill(Chief Executive Officer)inMichael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)inSoumya Raychaudhuri(Founder)David A. Tuveson(Founder)
Co-investorsGV (Google Ventures)ForbionJohnson & Johnson Innovation – JJDCNorthpond VenturesSV Health Investors
Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets.
AI & Machine LearningBiotechDeep Tech
Co-investorsM VenturesOxford Science EnterprisesPfizer Venture InvestmentsBritish Patient CapitalPfizer Ventures
HealthtechBend, US
Kirk Mansberger(Executive Officer, Director, Promoter)
Co-investorsSamsung Catalyst FundReward Funding
HealthtechCambridge, US
Adam Rosenberg(Executive Officer, Director)in
BoardBruce Booth(Director)Kees Been(Director)Samantha Singer(Director)
Co-investorsGV (Google Ventures)Hatteras Venture PartnersThird Point VenturesAtlas VentureRemeditex Ventures
Ronovo Surgical develops the Carina surgical robotics platform, including a vision system and instruments, for use by surgeons and hospitals.
HealthtechMedical DevicesRoboticsShanghai, CN
John Ma(Founder)inYing Mao(Founder)in
Co-investorsGranite AsiaINCE CapitalVivo CapitalLilly Asia Ventures
BiotechNew York, US
BoardIsaac Blech(Vice Chairman)William A. Haseltine(Director)Roger Pomerantz(Director)Robert Ruffolo(Director)
Co-investorsAdjuvant CapitalAlexandriaFounders FundJohnson & Johnson Innovation – JJDC
Exits · 1
IPOs and acquisitions across the tracked portfolioProtagonist TherapeuticsNASDAQ: PTGX
Portfolio news
latest coverage across their companies
Renovo · aol.co.uk · Aug 17, 2026
Protagonist Therapeutics · sahmcapital.com · Aug 6, 2026
Mestag Therapeutics · discover-pharma.com · May 5, 2026
Ronovo Surgical · fiercebiotech.com · Sep 9, 2025
Frequently asked questions
- What stage does JJDC invest at?
- JJDC invests at the Seed, Series A, Series B stages.
- What is JJDC's typical check size?
- JJDC typically writes checks of $500K – $5M.
- What sectors does JJDC focus on?
- JJDC focuses on Biotech, Consumer, Healthtech, Medical Devices.
- Where is JJDC located?
- JJDC is headquartered in New Brunswick, US.
Similar investors
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Norwest Venture Partners is an investment firm whose growth equity team backs private, profitable, fast-growing companies, providing capital and hands-on support through its 'invited guest' approach.
US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.
Shenzhen Capital Group (SZVC) is a Chinese venture capital and private equity investment firm that invests in and nurtures companies, with over 300 of its portfolio companies having gone public.
AZ Venture Capital (AVC) invests in early-stage technology startups and funds across multiple sectors, with a focus on expanding access to equity capital for founders and communities in Arizona.